The role of PET/CT in the evaluation of skeletal metastases

Seminars in Musculoskeletal Radiology

Volumn 18, Issue 2, 2014, Pages 149-165

  Kannivelu, Anbalagan ^a,b   Loke, Kelvin S H ^b   Kok, Tian Yue ^b   Osmany, Saabry Yusof ^c   Ali, Syed Zama ^a,b   Suat Jin, Lu ^d   Ng, David Chee Eng ^b  

^a KHOO TECK PUAT HOSPITAL   (Singapore)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

^c Singapore Science Park II   (Singapore)

^d MOUNT ELIZABETH MEDICAL CENTRE   (Singapore)

Author keywords

hybrid imaging; image fusion; skeletal metastases; skeletal scintigraphy; Tc 99m diphosphonate bone scan

Indexed keywords

FLUORODEOXYGLUCOSE F 18; SODIUM FLUORIDE F 18; TRACER;

ARTICLE; ARTIFACT; BONE METASTASIS; BONE RADIOGRAPHY; BONE SCINTISCANNING; BREAST CANCER; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; INTERMETHOD COMPARISON; KIDNEY CANCER; LUNG CANCER; LYMPHOMA; MULTIPLE MYELOMA; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION PHYSICS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THYROID CARCINOMA; BONE NEOPLASMS; BREAST TUMOR; CARCINOMA; FEMALE; HISTORY; KIDNEY TUMOR; LUNG TUMOR; MALE; PATHOLOGY; PROCEDURES; PROSTATE TUMOR; SECONDARY; THYROID TUMOR;

BONE NEOPLASMS; BREAST NEOPLASMS; CARCINOMA, NEUROENDOCRINE; FEMALE; HISTORY, ANCIENT; HUMANS; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE MYELOMA; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; THYROID NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84898460058     PISSN: 10897860     EISSN: 1098898X     Source Type: Journal    
DOI: 10.1055/s-0034-1371017     Document Type: Article

References (100)

1. Mundy G. R. Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer: 2002; 2 8 584 593 (Pubitemid 37328925)
2. Ziessman H. A., O'Malley J. P., Thrall J. H., Fahey F. H. Nuclear Medicine: The Requisites. 4th ed. Philadelphia, PA Elsevier/Saunders: 2014
3. Kahn D., Weiner G. J., Ben-Haim S., et al. Positron emission tomographic measurement of bone marrow blood flow to the pelvis and lumbar vertebrae in young normal adults. Blood: 1994; 83 4 958 963 (Pubitemid 24058545)
4. Edelstyn G. A., Gillespie P. J., Grebbell F. S. The radiological demonstration of osseous metastases. Experimental observations. Clin Radiol: 1967; 18 2 158 162
5. Peh W. C., Mutarak M. Imaging in bone metastases. Medscape Web site. Available at: http://emedicine.medscape.com/article/387840-overview. Updated March 8, 2013. Accessed December 17, 2013
6. Hamaoka T., Madewell J. E., Podoloff D. A., Hortobagyi G. N., Ueno N. T. Bone imaging in metastatic breast cancer. J Clin Oncol: 2004; 22 14 2942 2953 (Pubitemid 41079914)
7. Ghanem N., Lohrmann C., Engelhardt M., et al. Whole-body MRI in the detection of bone marrow infiltration in patients with plasma cell neoplasms in comparison to the radiological skeletal survey. Eur Radiol: 2006; 16 5 1005 1014
8. Rubens R. D. Bone metastases-incidence and complications. In: Rubens R. D., Mundy G. R., eds. Cancer and the Skeleton. London, UK Martin Dunitz: 2000; 33 42
9. Cook G. J. PET and PET/CT imaging of skeletal metastases. Cancer Imaging: 2010; 10 1 8
10. Blau M., Ganatra R., Bender M. A. 18 F-fluoride for bone imaging. Semin Nucl Med: 1972; 2 1 31 37
11. Blau M., Nagler W., Bender M. A. Fluorine-18: a new isotope for bone scanning. J Nucl Med: 1962; 3 332 334
12. Davis M. A., Jones A. L. Comparison of 99mTc-labeled phosphate and phosphonate agents for skeletal imaging. Semin Nucl Med: 1976; 6 1 19 31
13. Frost M. L., Blake G. M., Park-Holohan S. J., et al. Long-term precision of 18F-fluoride PET skeletal kinetic studies in the assessment of bone metabolism. J Nucl Med: 2008; 49 5 700 707 (Pubitemid 351717533)
14. Hoh C. K., Hawkins R. A., Dahlbom M., et al. Whole body skeletal imaging with [18F]fluoride ion and PET. J Comput Assist Tomogr: 1993; 17 1 34 41 (Pubitemid 23029796)
15. Gnanasegaran G., Cook G., Adamson K., Fogelman I. Patterns, variants, artifacts, and pitfalls in conventional radionuclide bone imaging and SPECT/CT. Semin Nucl Med: 2009; 39 6 380 395
16. Society of Nuclear Medicine Procedure guideline for bone scintigraphy, v.3.0, approved June 20, 2013. Available at: http://interactive.snm.org/docs/pg- ch34-0403.pdf. Accessed December 17, 2013
17. Galasko C. S. Skeletal metastases and mammary cancer. Ann R Coll Surg Engl: 1972; 50 1 3 28
18. Cook G. J., Fogelman I. Skeletal metastases from breast cancer: imaging with nuclear medicine. Semin Nucl Med: 1999; 29 1 69 79 (Pubitemid 29061432)
19. Hortobagyi G. N., Libshitz H. I., Seabold J. E. Osseous metastases of breast cancer. Clinical, biochemical, radiographic, and scintigraphic evaluation of response to therapy. Cancer: 1984; 53 3 577 582 (Pubitemid 14182740)
20. Perez D. J., Powles T. J., Milan J., et al. Detection of breast carcinoma metastases in bone: relative merits of X-rays and skeletal scintigraphy. Lancet: 1983; 2 8350 613 616 (Pubitemid 13051051)
21. Sudhakar P., Sharma A. R., Bhushan S. M., Ranadhir G., Narsimuhulu G., Rao V. V. Efficacy of SPECT over planar bone scan in the diagnosis of solitary vertebral lesions in patients with low back pain. Indian J Nucl Med: 2010; 25 2 44 48
22. Mettler F. A., Guiberteau M. J. Essentials of Nuclear Medicine Imaging. 6th ed. Philadelphia, PA Elsevier/Saunders: 2012
23. Fogelman I., Cook G., Israel O., Van der Wall H. Positron emission tomography and bone metastases. Semin Nucl Med: 2005; 35 2 135 142 (Pubitemid 40568746)
24. Minn H., Clavo A. C., Wahl R. L. Influence of hypoxia on tracer accumulation in squamous-cell carcinoma: in vitro evaluation for PET imaging. Nucl Med Biol: 1996; 23 8 941 946 (Pubitemid 27050680)
25. Society of Nuclear Medicine Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0. Approved February 11, 2006. Available at: http://interactive.snm.org/docs/jnm30551-online.pdf. Accessed December 17, 2013
26. Petrén-Mallmin M., Andréasson I., Ljunggren O., et al. Skeletal metastases from breast cancer: uptake of 18F-fluoride measured with positron emission tomography in correlation with CT. Skeletal Radiol: 1998; 27 2 72 76 (Pubitemid 28181733)
27. Blake G. M., Park-Holohan S. J., Fogelman I. Quantitative studies of bone in postmenopausal women using (18)F-fluoride and (99m)Tc-methylene diphosphonate. J Nucl Med: 2002; 43 3 338 345 (Pubitemid 34208095)
28. Grant F. D., Fahey F. H., Packard A. B., Davis R. T., Alavi A., Treves S. T. Skeletal PET with 18F-fluoride: applying new technology to an old tracer. J Nucl Med: 2008; 49 1 68 78
29. Society of Nuclear Medicine SNM practice guideline for sodium 18F-fluoride PET/CT bone scans 1.0. Approved June 4, 2010. Available at: http://snmmi.files.cms-plus.com/docs/MUSC-Sodium18F-with-PET-CT-Bone-V1-JNM.pdf. Accessed December 17, 2013
30. Kwee S. A., Wei H., Sesterhenn I., Yun D., Coel M. N. Localization of primary prostate cancer with dual-phase 18F-fluorocholine PET. J Nucl Med: 2006; 47 2 262 269 (Pubitemid 46780891)
31. Gabriel M., Decristoforo C., Kendler D., et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med: 2007; 48 4 508 518 (Pubitemid 47571404)
32. Blodgett T. M., Mehta A. S., Mehta A. S., Laymon C. M., Carney J., Townsend D. W. PET/CT artifacts. Clin Imaging: 2011; 35 1 49 63
33. Cook G. J., Fogelman I., Maisey M. N. Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: potential for error in interpretation. Semin Nucl Med: 1996; 26 4 308 314 (Pubitemid 126789027)
34. Clavo A. C., Brown R. S., Wahl R. L. Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia. J Nucl Med: 1995; 36 9 1625 1632
35. Bury T., Barreto A., Daenen F., Barthelemy N., Ghaye B., Rigo P. Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer. Eur J Nucl Med: 1998; 25 9 1244 1247 (Pubitemid 28446049)
36. Schirrmeister H., Guhlmann A., Elsner K., et al. Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET. J Nucl Med: 1999; 40 10 1623 1629 (Pubitemid 29471151)
37. Even-Sapir E., Metser U., Flusser G., et al. Assessment of malignant skeletal disease: initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT. J Nucl Med: 2004; 45 2 272 278 (Pubitemid 47618648)
38. Taira A. V., Herfkens R. J., Gambhir S. S., Quon A. Detection of bone metastases: assessment of integrated FDG PET/CT imaging. Radiology: 2007; 243 1 204 211 (Pubitemid 46579712)
39. Metser U., Lerman H., Blank A., Lievshitz G., Bokstein F., Even-Sapir E. Malignant involvement of the spine: assessment by 18F-FDG PET/CT. J Nucl Med: 2004; 45 2 279 284 (Pubitemid 47618649)
40. Damle N. A., Bal C., Bandopadhyaya G. P., et al. The role of 18F-fluoride PET-CT in the detection of bone metastases in patients with breast, lung and prostate carcinoma: a comparison with FDG PET/CT and 99mTc-MDP bone scan. Jpn J Radiol: 2013; 31 4 262 269
41. Stafford S. E., Gralow J. R., Schubert E. K., et al. Use of serial FDG PET to measure the response of bone-dominant breast cancer to therapy. Acad Radiol: 2002; 9 8 913 921 (Pubitemid 34856284)
42. International Agency for Research on Cancer (World Health Organization) GLOBOCAN 12: Estimated cancer incidence, mortality and prevalence worldwide in 2012. Available at: http://globocan.iarc.fr/Default.aspx. Published December 12, 2013. Accessed December 17, 2013
43. Cook G. J., Houston S., Rubens R., Maisey M. N., Fogelman I. Detection of bone metastases in breast cancer by 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol: 1998; 16 10 3375 3379 (Pubitemid 28481635)
44. Langsteger W., Heinisch M., Fogelman I. The role of fluorodeoxyglucose, 18F-dihydroxyphenylalanine, 18F-choline, and 18F-fluoride in bone imaging with emphasis on prostate and breast. Semin Nucl Med: 2006; 36 1 73 92 (Pubitemid 41782168)
45. Ben-Haim S., Israel O. Breast cancer: role of SPECT and PET in imaging bone metastases. Semin Nucl Med: 2009; 39 6 408 415
46. Schirrmeister H., Guhlmann A., Kotzerke J., et al. Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. J Clin Oncol: 1999; 17 8 2381 2389 (Pubitemid 29368236)
47. Damle N., Bal C., Bandopadhyaya G., Kumar L., Kumar P. Role of 18F fluoride PET/CT in the detection of bone metastases in breast cancer patients. J Nucl Med: 2007; 48 (Supplement 2): 142P
48. Dotan Z. A. Bone imaging in prostate cancer. Nat Clin Pract Urol: 2008; 5 8 434 444
49. Cook G. J., Fogelman I. The role of nuclear medicine in monitoring treatment in skeletal malignancy. Semin Nucl Med: 2001; 31 3 206 211 (Pubitemid 32565551)
50. Even-Sapir E., Metser U., Mishani E., Lievshitz G., Lerman H., Leibovitch I. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med: 2006; 47 2 287 297 (Pubitemid 46780894)
51. Beheshti M., Langsteger W., Fogelman I. Prostate cancer: role of SPECT and PET in imaging bone metastases. Semin Nucl Med: 2009; 39 6 396 407
52. Shreve P. D., Grossman H. B., Gross M. D., Wahl R. L. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. Radiology: 1996; 199 3 751 756
53. Oyama N., Akino H., Kanamaru H., et al. 11C-acetate PET imaging of prostate cancer. J Nucl Med: 2002; 43 2 181 186 (Pubitemid 34151040)
54. Oyama N., Miller T. R., Dehdashti F., et al. 11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. J Nucl Med: 2003; 44 4 549 555 (Pubitemid 39663421)
55. Sandblom G., Sörensen J., Lundin N., Häggman M., Malmström P. U. Positron emission tomography with C11-acetate for tumor detection and localization in patients with prostate-specific antigen relapse after radical prostatectomy. Urology: 2006; 67 5 996 1000 (Pubitemid 43956436)
56. Price D. T., Coleman R. E., Liao R. P., Robertson C. N., Polascik T. J., DeGrado T. R. Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer. J Urol: 2002; 168 1 273 280 (Pubitemid 34640843)
57. Schmid D. T., John H., Zweifel R., et al. Fluorocholine PET/CT in patients with prostate cancer: initial experience. Radiology: 2005; 235 2 623 628 (Pubitemid 40571106)
58. Beheshti M., Vali R., Waldenberger P., et al. Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study. Eur J Nucl Med Mol Imaging: 2008; 35 10 1766 1774
59. Alavi A., Kung J. W., Zhuang H. Implications of PET based molecular imaging on the current and future practice of medicine. Semin Nucl Med: 2004; 34 1 56 69 (Pubitemid 38056404)
60. Chua S., Gnanasegaran G., Cook G. J. Miscellaneous cancers (lung, thyroid, renal cancer, myeloma, and neuroendocrine tumors): role of SPECT and PET in imaging bone metastases. Semin Nucl Med: 2009; 39 6 416 430
61. Schirrmeister H., Glatting G., Hetzel J., et al. Prospective evaluation of the clinical value of planar bone scans, SPECT, and (18)F-labeled NaF PET in newly diagnosed lung cancer. J Nucl Med: 2001; 42 12 1800 1804 (Pubitemid 34016348)
62. Vinjamuri M., Craig M., Campbell-Fontaine A., Almubarak M., Gupta N., Rogers J. S. Can positron emission tomography be used as a staging tool for small-cell lung cancer? Clin Lung Cancer: 2008; 9 1 30 34 (Pubitemid 351251598)
63. Cheran S. K., Herndon J. E. II, Patz E. F. Jr. Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer. Lung Cancer: 2004; 44 3 317 325 (Pubitemid 38609440)
64. Hetzel M., Arslandemir C., König H-H., et al. F-18 NaF PET for detection of bone metastases in lung cancer: accuracy, cost-effectiveness, and impact on patient management. J Bone Miner Res: 2003; 18 12 2206 2214 (Pubitemid 37463314)
65. Krüger S., Buck A. K., Mottaghy F. M., et al. Detection of bone metastases in patients with lung cancer: 99mTc-MDP planar bone scintigraphy, 18F-fluoride PET or 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging: 2009; 36 11 1807 1812
66. Muresan M. M., Olivier P., Leclère J., et al. Bone metastases from differentiated thyroid carcinoma. Endocr Relat Cancer: 2008; 15 1 37 49 (Pubitemid 351449726)
67. Grünwald F., Menzel C., Bender H., et al. Comparison of 18FDG-PET with 131iodine and 99mTc-sestamibi scintigraphy in differentiated thyroid cancer. Thyroid: 1997; 7 3 327 335 (Pubitemid 27295127)
68. Schlüter B., Bohuslavizki K. H., Beyer W., Plotkin M., Buchert R., Clausen M. Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan. J Nucl Med: 2001; 42 1 71 76 (Pubitemid 32104780)
69. Kollender Y., Bickels J., Price W. M., et al. Metastatic renal cell carcinoma of bone: indications and technique of surgical intervention. J Urol: 2000; 164 5 1505 1508
70. Wu H. C., Yen R. F., Shen Y. Y., Kao C. H., Lin C. C., Lee C. C. Comparing whole body 18F-2-deoxyglucose positron emission tomography and technetium-99m methylene diphosphate bone scan to detect bone metastases in patients with renal cell carcinomas-a preliminary report. J Cancer Res Clin Oncol: 2002; 128 9 503 506
71. Schirrmeister H., Bommer M., Buck A. K., et al. Initial results in the assessment of multiple myeloma using 18F-FDG PET. Eur J Nucl Med Mol Imaging: 2002; 29 3 361 366 (Pubitemid 34253248)
72. Hung G-U, Tsai C-C, Tsai S-C, Lin W. Y. Comparison of Tc-99m sestamibi and F-18 FDG-PET in the assessment of multiple myeloma. Anticancer Res: 2005; 25 6C 4737 4741 (Pubitemid 41729539)
73. Fonti R., Salvatore B., Quarantelli M., et al. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma. J Nucl Med: 2008; 49 2 195 200 (Pubitemid 351225656)
74. Durie B. G., Kyle R. A., Belch A., et al. Scientific Advisors of the International Myeloma Foundation. Myeloma management guidelines: a consensus report from the Scientific Advisors of the International Myeloma Foundation. Hematol J: 2003; 4 6 379 398 (Pubitemid 38088783)
75. Oberg K. Neuroendocrine gastrointestinal tumors-a condensed overview of diagnosis and treatment. Ann Oncol: 1999; 10 02 S3 S8 (Pubitemid 29288524)
76. Rufini V., Calcagni M. L., Baum R. P. Imaging of neuroendocrine tumors. Semin Nucl Med: 2006; 36 3 228 247 (Pubitemid 43817847)
77. Scarsbrook A. F., Ganeshan A., Statham J., et al. Anatomic and functional imaging of metastatic carcinoid tumors. Radiographics: 2007; 27 2 455 477
78. Leboulleux S., Dromain C., Vataire A. L., et al. Prediction and diagnosis of bone metastases in well-differentiated gastro-entero-pancreatic endocrine cancer: a prospective comparison of whole body magnetic resonance imaging and somatostatin receptor scintigraphy. J Clin Endocrinol Metab: 2008; 93 8 3021 3028
79. Meijer W. G., van der Veer E., Jager P. L., et al. Bone metastases in carcinoid tumors: clinical features, imaging characteristics, and markers of bone metabolism. J Nucl Med: 2003; 44 2 184 191
80. Adams S., Baum R., Rink T., Schumm-Dräger P. M., Usadel K. H., Hör G. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med: 1998; 25 1 79 83 (Pubitemid 28107907)
81. Baum R. P., Niesen A., Leonhardi J., et al. Receptor PET/CT imaging of neuroendocrine tumors using theGa-68 labelled, high affinity somatostatin analogue DOTA-1-Nal3-octreotide (DOTA-NOC): clinical results in 327 patients. Eur J Nucl Med Mol Imaging: 2005; 32 S54
82. Moog F., Kotzerke J., Reske S. N. FDG PET can replace bone scintigraphy in primary staging of malignant lymphoma. J Nucl Med: 1999; 40 9 1407 1413 (Pubitemid 29428919)
83. Hollinger E. F., Alibazoglu H., Ali A., Green A., Lamonica G. Hematopoietic cytokine-mediated FDG uptake simulates the appearance of diffuse metastatic disease on whole-body PET imaging. Clin Nucl Med: 1998; 23 2 93 98 (Pubitemid 28104051)
84. Steinborn M. M., Heuck A. F., Tiling R., Bruegel M., Gauger L., Reiser M. F. Whole-body bone marrow MRI in patients with metastatic disease to the skeletal system. J Comput Assist Tomogr: 1999; 23 1 123 129 (Pubitemid 29095482)
85. Eustace S., Tello R., DeCarvalho V., et al. A comparison of whole-body turboSTIR MR imaging and planar 99mTc-methylene diphosphonate scintigraphy in the examination of patients with suspected skeletal metastases. AJR Am J Roentgenol: 1997; 169 6 1655 1661 (Pubitemid 127469800)
86. Jones A. L., Williams M. P., Powles T. J., et al. Magnetic resonance imaging in the detection of skeletal metastases in patients with breast cancer. Br J Cancer: 1990; 62 2 296 298 (Pubitemid 20242456)
87. Daldrup-Link H. E., Franzius C., Link T. M., et al. Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET. AJR Am J Roentgenol: 2001; 177 1 229 236 (Pubitemid 32578088)
88. 18DG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with lung cancer. Eur J Radiol: 2012; 81 5 1007 1015
89. Takenaka D., Ohno Y., Matsumoto K., et al. Detection of bone metastases in non-small cell lung cancer patients: comparison of whole-body diffusion-weighted imaging (DWI), whole-body MR imaging without and with DWI, whole-body FDG-PET/CT, and bone scintigraphy. J Magn Reson Imaging: 2009; 30 2 298 308
90. Mosavi F., Johansson S., Sandberg D. T., Turesson I., Sörensen J., Ahlström H. Whole-body diffusion-weighted MRI compared with (18)F-NaF PET/CT for detection of bone metastases in patients with high-risk prostate carcinoma. AJR Am J Roentgenol: 2012; 199 5 1114 1120
91. Buchbender C., Heusner T. A., Lauenstein T. C., Bockisch A., Antoch G. Oncologic PET/MRI, part 1: tumors of the brain, head and neck, chest, abdomen, and pelvis. J Nucl Med: 2012; 53 6 928 938
92. Podoloff D. A., Ball D. W., Ben-Josef E., et al. NCCN task force: clinical utility of PET in a variety of tumor types. J Natl Compr Canc Netw: 2009; 7 02 S1 S26
93. Savelli G., Maffioli L., Maccauro M., De Deckere E., Bombardieri E. Bone scintigraphy and the added value of SPECT (single photon emission tomography) in detecting skeletal lesions. Q J Nucl Med: 2001; 45 1 27 37 (Pubitemid 32586339)
94. Iagaru A., Mittra E., Mosci C., et al. Combined 18F-fluoride and 18F-FDG PET/CT scanning for evaluation of malignancy: results of an international multicenter trial. J Nucl Med: 2013; 54 2 176 183
95. Iagaru A., Mittra E., Yaghoubi S. S., et al. Novel strategy for a cocktail 18F-fluoride and 18F-FDG PET/CT scan for evaluation of malignancy: results of the pilot-phase study. J Nucl Med: 2009; 50 4 501 505
96. Kannivelu A., Kok T. Y., Padhy A. K. The conundrum of PET/MR. World J Nucl Med: 2012; 11 1 1 2
97. Drzezga A., Souvatzoglou M., Eiber M., et al. First clinical experience with integrated whole-body PET/MR: comparison to PET/CT in patients with oncologic diagnoses. J Nucl Med: 2012; 53 6 845 855
98. Imamura F., Kuriyama K., Seto T., et al. Detection of bone marrow metastases of small cell lung cancer with magnetic resonance imaging: early diagnosis before destruction of osseous structure and implications for staging. Lung Cancer: 2000; 27 3 189 197 (Pubitemid 30105658)
99. Reischauer C., Froehlich J. M., Koh D. M., et al. Bone metastases from prostate cancer: assessing treatment response by using diffusion-weighted imaging and functional diffusion maps-initial observations. Radiology: 2010; 257 2 523 531
100. Buchbender C., Heusner T. A., Lauenstein T. C., Bockisch A., Antoch G. Oncologic PET/MRI, part 2: bone tumors, soft-tissue tumors, melanoma, and lymphoma. J Nucl Med: 2012; 53 8 1244 1252